NASDAQ:RNAC Cartesian Therapeutics (RNAC) Stock Price, News & Analysis $6.75 0.00 (0.00%) Closing price 05/22/2026 04:00 PM EasternExtended Trading$6.75 0.00 (0.00%) As of 05/22/2026 04:10 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock About Cartesian Therapeutics Stock (NASDAQ:RNAC) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Cartesian Therapeutics alerts:Sign Up Key Stats Today's Range$6.50▼$7.0550-Day Range$5.85▼$8.7052-Week Range$5.60▼$15.57Volume109,018 shsAverage Volume173,106 shsMarket Capitalization$198.32 millionP/E RatioN/ADividend YieldN/APrice Target$33.00Consensus RatingModerate Buy Company Overview Cartesian Therapeutics, trading on NASDAQ under the symbol RNAC, is a clinical‐stage biotechnology company specializing in the development of messenger RNA (mRNA)-based therapeutics. The company leverages a proprietary RNA delivery platform to induce the production of therapeutic proteins within patients, aiming to address a range of diseases through in vivo expression of disease-modifying agents. Cartesian’s technology is designed to optimize mRNA stability, translation efficiency and targeted delivery, with potential applications spanning oncology, autoimmune disorders and rare genetic conditions. At the core of Cartesian’s approach is a synthetic mRNA platform that incorporates proprietary lipid nanoparticle (LNP) formulations. By combining nucleoside‐modified mRNA with bespoke LNP carriers, the company seeks to enhance cellular uptake and reduce immunogenicity, positioning its pipeline candidates for both systemic and localized therapeutic interventions. Cartesian’s preclinical programs include immuno-modulatory candidates intended to boost anti-tumor immunity, as well as mRNA constructs designed to reestablish immune tolerance in autoimmune disease models. The firm has also entered strategic collaborations with academic institutions and contract research organizations to support IND-enabling studies and expand its translational research capabilities. Founded as a spin-out from leading academic research laboratories, Cartesian Therapeutics completed its initial public offering in 2021. Headquartered in New Jersey, the company engages with a broad network of scientific and clinical partners across North America and Europe. Cartesian’s leadership team includes experienced executives drawn from both biotech start-ups and larger pharmaceutical organizations, underscoring its commitment to advancing mRNA science from bench to bedside. As Cartesian progresses toward clinical milestones, it aims to establish itself as a key innovator in the rapidly evolving field of RNA therapeutics.AI Generated. May Contain Errors. Read More Cartesian Therapeutics Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks53rd Percentile Overall ScoreRNAC MarketRank™: Cartesian Therapeutics scored higher than 53% of companies evaluated by MarketBeat, and ranked 470th out of 869 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion4.3 / 5Analyst RatingModerate Buy Consensus RatingCartesian Therapeutics has received a consensus rating of Moderate Buy. The company's average rating score is 2.67, and is based on no strong buy ratings, 5 buy ratings, no hold ratings, and 1 sell rating.Upside PotentialCartesian Therapeutics has a consensus price target of $33.00, representing about 388.9% upside from its current price of $6.75.Amount of Analyst CoverageCartesian Therapeutics has been the subject of 6 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about Cartesian Therapeutics' stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for Cartesian Therapeutics are expected to grow in the coming year, from ($4.02) to ($3.63) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Cartesian Therapeutics is -1.14, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Cartesian Therapeutics is -1.14, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Read more about Cartesian Therapeutics' valuation and earnings. Short Interest1.0 / 5Short Interest LevelBearish Percentage of Shares Shorted11.76% of the float of Cartesian Therapeutics has been sold short.Short Interest Ratio / Days to CoverCartesian Therapeutics has a short interest ratio ("days to cover") of 12.79, which indicates bearish sentiment.Change versus previous monthShort interest in Cartesian Therapeutics has recently decreased by 2.04%, indicating that investor sentiment is improving. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldCartesian Therapeutics does not currently pay a dividend.Dividend GrowthCartesian Therapeutics does not have a long track record of dividend growth. News and Social Media1.3 / 5News SentimentN/A News Coverage This WeekMarketBeat has tracked 1 news article for Cartesian Therapeutics this week, compared to 2 articles on an average week.Search Interest1 people have searched for RNAC on MarketBeat in the last 30 days. MarketBeat Follows3 people have added Cartesian Therapeutics to their MarketBeat watchlist in the last 30 days. Company Ownership1.4 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Cartesian Therapeutics insiders have not sold or bought any company stock.Percentage Held by Insiders37.20% of the stock of Cartesian Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions86.95% of the stock of Cartesian Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Cartesian Therapeutics' insider trading history. Receive RNAC Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Cartesian Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. RNAC Stock News HeadlinesCartesian Therapeutics, Inc. (NASDAQ:RNAC) Given Consensus Rating of "Moderate Buy" by AnalystsMay 21, 2026 | americanbankingnews.comWe're Keeping An Eye On Cartesian Therapeutics' (NASDAQ:RNAC) Cash Burn RateMay 17, 2026 | finance.yahoo.comBefore you buy SpaceX shares, consider this alternative approachSpaceX has confidentially filed for an IPO with the SEC, targeting a June 2026 listing at a valuation exceeding $1.75 trillion - potentially the largest IPO in history. But one expert says buying shares directly may not be the smartest move. There is a lesser-known way to tap into this windfall that most investors haven't considered.May 25 at 1:00 AM | Weiss Ratings (Ad)Cartesian Therapeutics to Participate in H.C. Wainwright 4th Annual BioConnect Investor ConferenceMay 12, 2026 | quiverquant.comQCartesian Therapeutics to Participate in the H.C. Wainwright 4th Annual BioConnect Investor Conference at NASDAQMay 12, 2026 | globenewswire.comCartesian Therapeutics Announces New Employment Inducement GrantsMay 4, 2026 | globenewswire.comAnalysts Have Conflicting Sentiments on These Healthcare Companies: Cartesian Therapeutics (RNAC) and Humana (HUM)May 2, 2026 | theglobeandmail.comCartesian Therapeutics Reports First Quarter 2026 Financial Results and Provides Business UpdateApril 30, 2026 | globenewswire.comSee More Headlines RNAC Stock Analysis - Frequently Asked Questions How have RNAC shares performed this year? Cartesian Therapeutics' stock was trading at $7.21 at the start of the year. Since then, RNAC shares have decreased by 6.4% and is now trading at $6.75. How were Cartesian Therapeutics' earnings last quarter? Cartesian Therapeutics, Inc. (NASDAQ:RNAC) issued its earnings results on Thursday, April, 30th. The company reported ($1.46) EPS for the quarter, missing the consensus estimate of ($0.84) by $0.62. The firm earned $0.08 million during the quarter, compared to analyst estimates of $0.22 million. When did Cartesian Therapeutics' stock split? Cartesian Therapeutics shares reverse split on the morning of Friday, April 5th 2024.The 1-30 reverse split was announced on Friday, April 5th 2024. The number of shares owned by shareholders was adjusted after the closing bell on Friday, April 5th 2024. An investor that had 100 shares of stock prior to the reverse split would have 3 shares after the split. When did Cartesian Therapeutics IPO? Cartesian Therapeutics (RNAC) raised $75 million in an IPO on Tuesday, June 21st 2016. The company issued 5,000,000 shares at a price of $14.00-$16.00 per share. Who are Cartesian Therapeutics' major shareholders? Cartesian Therapeutics' top institutional shareholders include Renaissance Technologies LLC (0.23%), Public Employees Retirement System of Ohio (0.04%) and Sei Investments Co. (0.04%). Insiders that own company stock include Timothy A Springer, Blaine Davis, Metin Kurtoglu and Milos Miljkovic. View institutional ownership trends. How do I buy shares of Cartesian Therapeutics? Shares of RNAC stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Cartesian Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some other companies that Cartesian Therapeutics investors own include NVIDIA (NVDA), Advanced Micro Devices (AMD), Meta Platforms (META), Tesla (TSLA), Netflix (NFLX), JPMorgan Chase & Co. (JPM) and Alphabet (GOOG). Company Calendar Last Earnings4/30/2026Today5/25/2026Next Earnings (Estimated)8/06/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Red Zone (6m+) 1-Year History May 25 Aug 25 Nov 25 Feb 26 May 26 RNAC's financial health is in the Red zone, according to TradeSmith. RNAC has been in this zone for over 6 months. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry MED - BIOMED/GENE Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:RNAC Previous SymbolNASDAQ:RNAC CIK1453687 Webselectabio.com Phone617-923-1400Fax617-924-3454Employees64Year Founded2016Price Target and Rating Average Price Target for Cartesian Therapeutics$33.00 High Price Target$44.00 Low Price Target$16.00 Potential Upside/Downside+388.9%Consensus RatingModerate Buy Rating Score (0-4)2.67 Research Coverage6 Analysts Profitability EPS (Trailing Twelve Months)($5.90) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$130.30 million Net Margins-8,550.65% Pretax Margin-9,068.56% Return on EquityN/A Return on Assets-28.25% Debt Debt-to-Equity RatioN/A Current Ratio7.65 Quick Ratio7.65 Sales & Book Value Annual Sales$2.80 million Price / Sales70.83 Cash FlowN/A Price / Cash FlowN/A Book Value($5.04) per share Price / Book-1.34Miscellaneous Outstanding Shares29,380,000Free Float18,452,000Market Cap$198.32 million OptionableOptionable Beta0.58 Social Links 7 Stocks to Ride The A.I. MegaboomWe are about to experience the greatest A.I. boom in stock market history... Thanks to a pivotal economic catalyst, specific tech stocks will skyrocket just like they did during the "dot com" boom in the 1990s. That’s why, we’ve hand-selected 7 tiny tech disruptor stocks positioned to surge. The first pick is a tiny under-the-radar A.I. stock that's trading for just $3.00. This company already has 98 registered patents for cutting-edge voice and sound recognition technology... And has lined up major partnerships with some of the biggest names in the auto, tech, and music industry... plus many more. The second pick presents an affordable avenue to bolster EVs and AI development…. Analysts are calling this stock a “buy” right now and predict a high price target of $19.20, substantially more than its current $6 trading price. Our final and favorite pick is generating a brand-new kind of AI. It's believed this tech will be bigger than the current well-known leader in this industry… Analysts predict this innovative tech is gearing up to create a tidal wave of new wealth, fueling a $15.7 TRILLION market boom. Right now, we’re staring down the barrel of a true once-in-a-lifetime moment. As an investment opportunity, this kind of breakthrough doesn't come along every day. And the window to get in on the ground-floor — maximizing profit potential from this expected market surge — is closing quickly... Simply click the link below to get the names and tickers of the 7 small stocks with potential to make investors very, very happy. Get This Free Report This page (NASDAQ:RNAC) was last updated on 5/25/2026 by MarketBeat.com Staff. From Our PartnersSpaceX eyes a 1.75 trillion valuation - here's what to knowElon Musk's team has quietly filed confidential paperwork with the SEC for what Bloomberg estimates could be a...Brownstone Research | Sponsored$30 stock to buy before Starlink goes public (WATCH NOW!)In the next 3 minutes… James Altucher – legendary investor and venture capitalist… And someone who’s kno...Paradigm Press | SponsoredMy feud with Zohran MamdaniEmmy-winning analyst releases his next big story Whitney Tilson shocked the nation on 60 Minutes when he ac...Stansberry Research | SponsoredYour book attachedBill Poulos is giving away his 'Safe Trade Options Formula' book for free - but only for a limited time throug...Profits Run | SponsoredSpaceX IPO hides a much bigger storyThe SpaceX IPO could be the biggest in history at $1.75 trillion - but the real story isn't the IPO itself. ...Weiss Ratings | SponsoredRead now. Do not delete. You’ve been warned.Three Nobel Prize Winners expose this once-in-a-generation wealth shift: “Don’t Say I Didn’t Warn You” P...Porter & Company | SponsoredSatellite Images Spot Potential $10 Trillion Discovery'Dark Energy': Elon Musk's Next Potential $10 Trillion Move A highly secure site in West Texas now houses a...Altimetry | SponsoredSpaceX will mint billionaires. You won't be one of them.By the time a company goes public, 95% of profits have already been made. Insiders bought SpaceX at $20 billio...Behind the Markets | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Cartesian Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Cartesian Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
